nodes	percent_of_prediction	percent_of_DWPC	metapath
Acamprosate—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00328	0.00491	CcSEcCtD
Acamprosate—Abnormal vision—Capecitabine—esophageal cancer	0.00323	0.00483	CcSEcCtD
Acamprosate—Mental disability—Capecitabine—esophageal cancer	0.00321	0.0048	CcSEcCtD
Acamprosate—Phlebitis—Capecitabine—esophageal cancer	0.00312	0.00466	CcSEcCtD
Acamprosate—Thrombophlebitis—Capecitabine—esophageal cancer	0.00311	0.00464	CcSEcCtD
Acamprosate—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00309	0.00462	CcSEcCtD
Acamprosate—Diabetes mellitus—Capecitabine—esophageal cancer	0.00309	0.00462	CcSEcCtD
Acamprosate—Pancreatitis—Cisplatin—esophageal cancer	0.00309	0.00462	CcSEcCtD
Acamprosate—Polyuria—Capecitabine—esophageal cancer	0.00306	0.00457	CcSEcCtD
Acamprosate—Gastroenteritis—Capecitabine—esophageal cancer	0.00303	0.00453	CcSEcCtD
Acamprosate—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00303	0.00453	CcSEcCtD
Acamprosate—Deafness—Capecitabine—esophageal cancer	0.00301	0.00449	CcSEcCtD
Acamprosate—Hyperuricaemia—Methotrexate—esophageal cancer	0.00297	0.00444	CcSEcCtD
Acamprosate—Renal failure acute—Capecitabine—esophageal cancer	0.00291	0.00435	CcSEcCtD
Acamprosate—Libido decreased—Capecitabine—esophageal cancer	0.0029	0.00433	CcSEcCtD
Acamprosate—Amnesia—Capecitabine—esophageal cancer	0.00286	0.00428	CcSEcCtD
Acamprosate—Increased appetite—Capecitabine—esophageal cancer	0.00286	0.00428	CcSEcCtD
Acamprosate—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00285	0.00426	CcSEcCtD
Acamprosate—Thirst—Capecitabine—esophageal cancer	0.00283	0.00422	CcSEcCtD
Acamprosate—Dermatitis bullous—Capecitabine—esophageal cancer	0.00281	0.0042	CcSEcCtD
Acamprosate—Blood uric acid increased—Methotrexate—esophageal cancer	0.00281	0.00419	CcSEcCtD
Acamprosate—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00277	0.00414	CcSEcCtD
Acamprosate—Arthritis—Capecitabine—esophageal cancer	0.00277	0.00413	CcSEcCtD
Acamprosate—Pulmonary embolism—Methotrexate—esophageal cancer	0.00276	0.00412	CcSEcCtD
Acamprosate—Vaginal inflammation—Methotrexate—esophageal cancer	0.00276	0.00412	CcSEcCtD
Acamprosate—Myocardial infarction—Cisplatin—esophageal cancer	0.00276	0.00412	CcSEcCtD
Acamprosate—Cardiac failure—Capecitabine—esophageal cancer	0.00276	0.00412	CcSEcCtD
Acamprosate—Stomatitis—Cisplatin—esophageal cancer	0.00274	0.00409	CcSEcCtD
Acamprosate—Hyponatraemia—Capecitabine—esophageal cancer	0.0027	0.00403	CcSEcCtD
Acamprosate—Melaena—Methotrexate—esophageal cancer	0.00269	0.00402	CcSEcCtD
Acamprosate—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00269	0.00402	CcSEcCtD
Acamprosate—Diplopia—Capecitabine—esophageal cancer	0.00269	0.00402	CcSEcCtD
Acamprosate—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00267	0.00398	CcSEcCtD
Acamprosate—Migraine—Capecitabine—esophageal cancer	0.00265	0.00395	CcSEcCtD
Acamprosate—Vaginal infection—Methotrexate—esophageal cancer	0.0026	0.00389	CcSEcCtD
Acamprosate—Face oedema—Capecitabine—esophageal cancer	0.0026	0.00388	CcSEcCtD
Acamprosate—Blood creatinine increased—Capecitabine—esophageal cancer	0.00252	0.00376	CcSEcCtD
Acamprosate—Ecchymosis—Methotrexate—esophageal cancer	0.00249	0.00372	CcSEcCtD
Acamprosate—Mouth ulceration—Methotrexate—esophageal cancer	0.00249	0.00372	CcSEcCtD
Acamprosate—Urine output increased—Methotrexate—esophageal cancer	0.00249	0.00372	CcSEcCtD
Acamprosate—Liver function test abnormal—Capecitabine—esophageal cancer	0.00248	0.00371	CcSEcCtD
Acamprosate—Dry skin—Capecitabine—esophageal cancer	0.00246	0.00368	CcSEcCtD
Acamprosate—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00246	0.00367	CcSEcCtD
Acamprosate—Visual impairment—Cisplatin—esophageal cancer	0.00243	0.00363	CcSEcCtD
Acamprosate—Breast disorder—Capecitabine—esophageal cancer	0.00243	0.00363	CcSEcCtD
Acamprosate—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.00242	0.00362	CcSEcCtD
Acamprosate—Gastritis—Capecitabine—esophageal cancer	0.00238	0.00355	CcSEcCtD
Acamprosate—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00237	0.00354	CcSEcCtD
Acamprosate—GRIN1—EPH-Ephrin signaling—ACTB—esophageal cancer	0.00235	0.00712	CbGpPWpGaD
Acamprosate—Tinnitus—Cisplatin—esophageal cancer	0.00235	0.00351	CcSEcCtD
Acamprosate—Lymphadenopathy—Methotrexate—esophageal cancer	0.00235	0.0035	CcSEcCtD
Acamprosate—Abdominal distension—Capecitabine—esophageal cancer	0.00234	0.00349	CcSEcCtD
Acamprosate—GABRA1—GABA receptor activation—GNG7—esophageal cancer	0.00234	0.00707	CbGpPWpGaD
Acamprosate—Dysphagia—Capecitabine—esophageal cancer	0.00232	0.00347	CcSEcCtD
Acamprosate—Asthma—Capecitabine—esophageal cancer	0.00232	0.00347	CcSEcCtD
Acamprosate—Influenza—Capecitabine—esophageal cancer	0.00232	0.00347	CcSEcCtD
Acamprosate—Thrombophlebitis—Methotrexate—esophageal cancer	0.00231	0.00345	CcSEcCtD
Acamprosate—Diabetes mellitus—Methotrexate—esophageal cancer	0.0023	0.00344	CcSEcCtD
Acamprosate—GRIN2B—EPH-Ephrin signaling—ACTB—esophageal cancer	0.00229	0.00694	CbGpPWpGaD
Acamprosate—Polyuria—Methotrexate—esophageal cancer	0.00228	0.00341	CcSEcCtD
Acamprosate—Immune system disorder—Cisplatin—esophageal cancer	0.00228	0.0034	CcSEcCtD
Acamprosate—Angina pectoris—Capecitabine—esophageal cancer	0.00226	0.00338	CcSEcCtD
Acamprosate—Bronchitis—Capecitabine—esophageal cancer	0.00223	0.00334	CcSEcCtD
Acamprosate—Alopecia—Cisplatin—esophageal cancer	0.00223	0.00333	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—LGALS3—esophageal cancer	0.00221	0.00668	CbGpPWpGaD
Acamprosate—Malnutrition—Cisplatin—esophageal cancer	0.0022	0.00328	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—CRTC1—esophageal cancer	0.00218	0.0066	CbGpPWpGaD
Acamprosate—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00217	0.00658	CbGpPWpGaD
Acamprosate—Renal failure acute—Methotrexate—esophageal cancer	0.00217	0.00324	CcSEcCtD
Acamprosate—Flatulence—Cisplatin—esophageal cancer	0.00216	0.00323	CcSEcCtD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00214	0.00648	CbGpPWpGaD
Acamprosate—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00212	0.00317	CcSEcCtD
Acamprosate—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00212	0.00317	CcSEcCtD
Acamprosate—Weight increased—Capecitabine—esophageal cancer	0.00211	0.00316	CcSEcCtD
Acamprosate—Muscle spasms—Cisplatin—esophageal cancer	0.00211	0.00315	CcSEcCtD
Acamprosate—Weight decreased—Capecitabine—esophageal cancer	0.0021	0.00314	CcSEcCtD
Acamprosate—Hyperglycaemia—Capecitabine—esophageal cancer	0.0021	0.00313	CcSEcCtD
Acamprosate—Pneumonia—Capecitabine—esophageal cancer	0.00208	0.00311	CcSEcCtD
Acamprosate—Depression—Capecitabine—esophageal cancer	0.00207	0.00309	CcSEcCtD
Acamprosate—Tremor—Cisplatin—esophageal cancer	0.00206	0.00307	CcSEcCtD
Acamprosate—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00204	0.00305	CcSEcCtD
Acamprosate—Ill-defined disorder—Cisplatin—esophageal cancer	0.00204	0.00304	CcSEcCtD
Acamprosate—Myocardial infarction—Capecitabine—esophageal cancer	0.00203	0.00303	CcSEcCtD
Acamprosate—Anaemia—Cisplatin—esophageal cancer	0.00203	0.00303	CcSEcCtD
Acamprosate—Stomatitis—Capecitabine—esophageal cancer	0.00202	0.00302	CcSEcCtD
Acamprosate—Urinary tract infection—Capecitabine—esophageal cancer	0.00201	0.00301	CcSEcCtD
Acamprosate—GRIN2C—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00201	0.00607	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.002	0.00605	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00199	0.00602	CbGpPWpGaD
Acamprosate—Malaise—Cisplatin—esophageal cancer	0.00198	0.00296	CcSEcCtD
Acamprosate—Haematuria—Capecitabine—esophageal cancer	0.00198	0.00295	CcSEcCtD
Acamprosate—GRIN1—BDNF signaling pathway—CFL1—esophageal cancer	0.00197	0.00595	CbGpPWpGaD
Acamprosate—Leukopenia—Cisplatin—esophageal cancer	0.00197	0.00294	CcSEcCtD
Acamprosate—Epistaxis—Capecitabine—esophageal cancer	0.00195	0.00292	CcSEcCtD
Acamprosate—GRIN2B—BDNF signaling pathway—CFL1—esophageal cancer	0.00192	0.0058	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CXCL2—esophageal cancer	0.00192	0.0058	CbGpPWpGaD
Acamprosate—Convulsion—Cisplatin—esophageal cancer	0.0019	0.00284	CcSEcCtD
Acamprosate—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.0019	0.00574	CbGpPWpGaD
Acamprosate—Myalgia—Cisplatin—esophageal cancer	0.00187	0.00279	CcSEcCtD
Acamprosate—Haemoglobin—Capecitabine—esophageal cancer	0.00187	0.00279	CcSEcCtD
Acamprosate—GABRB3—Ion channel transport—ATP1B2—esophageal cancer	0.00187	0.00565	CbGpPWpGaD
Acamprosate—GRIN2D—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00187	0.00564	CbGpPWpGaD
Acamprosate—Rhinitis—Capecitabine—esophageal cancer	0.00186	0.00279	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00186	0.00564	CbGpPWpGaD
Acamprosate—Anxiety—Cisplatin—esophageal cancer	0.00186	0.00278	CcSEcCtD
Acamprosate—Hepatitis—Capecitabine—esophageal cancer	0.00186	0.00278	CcSEcCtD
Acamprosate—Haemorrhage—Capecitabine—esophageal cancer	0.00186	0.00278	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00186	0.00277	CcSEcCtD
Acamprosate—Hypoaesthesia—Capecitabine—esophageal cancer	0.00185	0.00276	CcSEcCtD
Acamprosate—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00185	0.00559	CbGpPWpGaD
Acamprosate—Liver function test abnormal—Methotrexate—esophageal cancer	0.00185	0.00276	CcSEcCtD
Acamprosate—Discomfort—Cisplatin—esophageal cancer	0.00185	0.00276	CcSEcCtD
Acamprosate—Pharyngitis—Capecitabine—esophageal cancer	0.00185	0.00276	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00185	0.00558	CbGpPWpGaD
Acamprosate—GRIN2B—ErbB4 signaling events—ERBB2—esophageal cancer	0.00183	0.00555	CbGpPWpGaD
Acamprosate—GABRG2—Ion channel transport—ATP1B2—esophageal cancer	0.00183	0.00555	CbGpPWpGaD
Acamprosate—Oedema peripheral—Capecitabine—esophageal cancer	0.00183	0.00274	CcSEcCtD
Acamprosate—Breast disorder—Methotrexate—esophageal cancer	0.00181	0.0027	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.0018	0.00543	CbGpPWpGaD
Acamprosate—Anaphylactic shock—Cisplatin—esophageal cancer	0.00179	0.00268	CcSEcCtD
Acamprosate—Visual impairment—Capecitabine—esophageal cancer	0.00179	0.00268	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00178	0.00539	CbGpPWpGaD
Acamprosate—GRM5—GPCR ligand binding—GNG7—esophageal cancer	0.00178	0.00539	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—ANXA1—esophageal cancer	0.00178	0.00539	CbGpPWpGaD
Acamprosate—Infection—Cisplatin—esophageal cancer	0.00178	0.00266	CcSEcCtD
Acamprosate—GRIN2C—Alzheimers Disease—CASP8—esophageal cancer	0.00177	0.00535	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00176	0.00531	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Cisplatin—esophageal cancer	0.00176	0.00262	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00175	0.0053	CbGpPWpGaD
Acamprosate—Tachycardia—Cisplatin—esophageal cancer	0.00175	0.00261	CcSEcCtD
Acamprosate—Skin disorder—Cisplatin—esophageal cancer	0.00174	0.0026	CcSEcCtD
Acamprosate—Tinnitus—Capecitabine—esophageal cancer	0.00173	0.00259	CcSEcCtD
Acamprosate—Hyperhidrosis—Cisplatin—esophageal cancer	0.00173	0.00259	CcSEcCtD
Acamprosate—Asthma—Methotrexate—esophageal cancer	0.00173	0.00258	CcSEcCtD
Acamprosate—Eosinophilia—Methotrexate—esophageal cancer	0.00171	0.00256	CcSEcCtD
Acamprosate—Anorexia—Cisplatin—esophageal cancer	0.00171	0.00255	CcSEcCtD
Acamprosate—Pancreatitis—Methotrexate—esophageal cancer	0.0017	0.00253	CcSEcCtD
Acamprosate—Immune system disorder—Capecitabine—esophageal cancer	0.00168	0.00251	CcSEcCtD
Acamprosate—Hypotension—Cisplatin—esophageal cancer	0.00168	0.0025	CcSEcCtD
Acamprosate—Chills—Capecitabine—esophageal cancer	0.00167	0.00249	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00166	0.00503	CbGpPWpGaD
Acamprosate—Alopecia—Capecitabine—esophageal cancer	0.00164	0.00246	CcSEcCtD
Acamprosate—GRIN2D—Alzheimers Disease—CASP8—esophageal cancer	0.00164	0.00497	CbGpPWpGaD
Acamprosate—GRIN2C—Neuronal System—GNG7—esophageal cancer	0.00164	0.00496	CbGpPWpGaD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00163	0.00495	CbGpPWpGaD
Acamprosate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00163	0.00244	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00163	0.00493	CbGpPWpGaD
Acamprosate—Mental disorder—Capecitabine—esophageal cancer	0.00163	0.00243	CcSEcCtD
Acamprosate—Malnutrition—Capecitabine—esophageal cancer	0.00162	0.00242	CcSEcCtD
Acamprosate—GABRB3—Ion channel transport—ATP4A—esophageal cancer	0.00162	0.0049	CbGpPWpGaD
Acamprosate—Paraesthesia—Cisplatin—esophageal cancer	0.00161	0.0024	CcSEcCtD
Acamprosate—GABRA1—Ion channel transport—ATP1B2—esophageal cancer	0.0016	0.00485	CbGpPWpGaD
Acamprosate—Dyspnoea—Cisplatin—esophageal cancer	0.0016	0.00239	CcSEcCtD
Acamprosate—Flatulence—Capecitabine—esophageal cancer	0.0016	0.00238	CcSEcCtD
Acamprosate—Erectile dysfunction—Methotrexate—esophageal cancer	0.00159	0.00238	CcSEcCtD
Acamprosate—GABRG2—Ion channel transport—ATP4A—esophageal cancer	0.00159	0.00481	CbGpPWpGaD
Acamprosate—Dysgeusia—Capecitabine—esophageal cancer	0.00159	0.00237	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00159	0.0048	CbGpPWpGaD
Acamprosate—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00158	0.00236	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—CXCL2—esophageal cancer	0.00157	0.00475	CbGpPWpGaD
Acamprosate—Back pain—Capecitabine—esophageal cancer	0.00157	0.00234	CcSEcCtD
Acamprosate—Decreased appetite—Cisplatin—esophageal cancer	0.00156	0.00233	CcSEcCtD
Acamprosate—Muscle spasms—Capecitabine—esophageal cancer	0.00156	0.00233	CcSEcCtD
Acamprosate—GRIN2A—Reelin signaling pathway—PIK3CA—esophageal cancer	0.00155	0.00469	CbGpPWpGaD
Acamprosate—Pneumonia—Methotrexate—esophageal cancer	0.00155	0.00232	CcSEcCtD
Acamprosate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00155	0.00231	CcSEcCtD
Acamprosate—Depression—Methotrexate—esophageal cancer	0.00154	0.0023	CcSEcCtD
Acamprosate—GRIN2C—Neuronal System—ALDH2—esophageal cancer	0.00154	0.00465	CbGpPWpGaD
Acamprosate—Pain—Cisplatin—esophageal cancer	0.00153	0.00229	CcSEcCtD
Acamprosate—GRIN2A—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00153	0.00463	CbGpPWpGaD
Acamprosate—GRIN2D—Neuronal System—GNG7—esophageal cancer	0.00153	0.00461	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00152	0.0046	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00152	0.0046	CbGpPWpGaD
Acamprosate—Tremor—Capecitabine—esophageal cancer	0.00152	0.00227	CcSEcCtD
Acamprosate—Stomatitis—Methotrexate—esophageal cancer	0.0015	0.00225	CcSEcCtD
Acamprosate—Ill-defined disorder—Capecitabine—esophageal cancer	0.0015	0.00224	CcSEcCtD
Acamprosate—Anaemia—Capecitabine—esophageal cancer	0.0015	0.00224	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—GDI2—esophageal cancer	0.0015	0.00452	CbGpPWpGaD
Acamprosate—Sweating—Methotrexate—esophageal cancer	0.00148	0.00221	CcSEcCtD
Acamprosate—Feeling abnormal—Cisplatin—esophageal cancer	0.00148	0.00221	CcSEcCtD
Acamprosate—Haematuria—Methotrexate—esophageal cancer	0.00147	0.0022	CcSEcCtD
Acamprosate—Malaise—Capecitabine—esophageal cancer	0.00146	0.00218	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—ANXA1—esophageal cancer	0.00146	0.00441	CbGpPWpGaD
Acamprosate—Epistaxis—Methotrexate—esophageal cancer	0.00145	0.00217	CcSEcCtD
Acamprosate—Vertigo—Capecitabine—esophageal cancer	0.00145	0.00217	CcSEcCtD
Acamprosate—Syncope—Capecitabine—esophageal cancer	0.00145	0.00217	CcSEcCtD
Acamprosate—Leukopenia—Capecitabine—esophageal cancer	0.00145	0.00217	CcSEcCtD
Acamprosate—Palpitations—Capecitabine—esophageal cancer	0.00143	0.00214	CcSEcCtD
Acamprosate—GRIN2D—Neuronal System—ALDH2—esophageal cancer	0.00143	0.00432	CbGpPWpGaD
Acamprosate—GRIN1—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00143	0.00431	CbGpPWpGaD
Acamprosate—Loss of consciousness—Capecitabine—esophageal cancer	0.00142	0.00213	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—SST—esophageal cancer	0.00142	0.00429	CbGpPWpGaD
Acamprosate—Body temperature increased—Cisplatin—esophageal cancer	0.00142	0.00212	CcSEcCtD
Acamprosate—Cough—Capecitabine—esophageal cancer	0.00141	0.00211	CcSEcCtD
Acamprosate—Hypertension—Capecitabine—esophageal cancer	0.0014	0.00209	CcSEcCtD
Acamprosate—Haemoglobin—Methotrexate—esophageal cancer	0.00139	0.00208	CcSEcCtD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00139	0.0042	CbGpPWpGaD
Acamprosate—GABRA1—Ion channel transport—ATP4A—esophageal cancer	0.00139	0.0042	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00139	0.00419	CbGpPWpGaD
Acamprosate—Hepatitis—Methotrexate—esophageal cancer	0.00138	0.00207	CcSEcCtD
Acamprosate—Haemorrhage—Methotrexate—esophageal cancer	0.00138	0.00207	CcSEcCtD
Acamprosate—GRM5—GPCR ligand binding—GHRL—esophageal cancer	0.00138	0.00418	CbGpPWpGaD
Acamprosate—Arthralgia—Capecitabine—esophageal cancer	0.00138	0.00206	CcSEcCtD
Acamprosate—Myalgia—Capecitabine—esophageal cancer	0.00138	0.00206	CcSEcCtD
Acamprosate—Chest pain—Capecitabine—esophageal cancer	0.00138	0.00206	CcSEcCtD
Acamprosate—Pharyngitis—Methotrexate—esophageal cancer	0.00137	0.00205	CcSEcCtD
Acamprosate—Anxiety—Capecitabine—esophageal cancer	0.00137	0.00205	CcSEcCtD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00137	0.00205	CcSEcCtD
Acamprosate—Discomfort—Capecitabine—esophageal cancer	0.00136	0.00203	CcSEcCtD
Acamprosate—GRIN2A—Alzheimers Disease—CASP8—esophageal cancer	0.00135	0.00408	CbGpPWpGaD
Acamprosate—Dry mouth—Capecitabine—esophageal cancer	0.00135	0.00201	CcSEcCtD
Acamprosate—GRIN1—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00134	0.00404	CbGpPWpGaD
Acamprosate—Visual impairment—Methotrexate—esophageal cancer	0.00133	0.00199	CcSEcCtD
Acamprosate—Confusional state—Capecitabine—esophageal cancer	0.00133	0.00199	CcSEcCtD
Acamprosate—Hypersensitivity—Cisplatin—esophageal cancer	0.00132	0.00197	CcSEcCtD
Acamprosate—GRIN2B—Reelin signaling pathway—PIK3CA—esophageal cancer	0.00132	0.00399	CbGpPWpGaD
Acamprosate—Infection—Capecitabine—esophageal cancer	0.00131	0.00196	CcSEcCtD
Acamprosate—GRIN2B—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.0013	0.00394	CbGpPWpGaD
Acamprosate—Shock—Capecitabine—esophageal cancer	0.0013	0.00194	CcSEcCtD
Acamprosate—GABRB3—BDNF signaling pathway—CFL1—esophageal cancer	0.0013	0.00393	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Capecitabine—esophageal cancer	0.00129	0.00193	CcSEcCtD
Acamprosate—Tinnitus—Methotrexate—esophageal cancer	0.00129	0.00193	CcSEcCtD
Acamprosate—Tachycardia—Capecitabine—esophageal cancer	0.00129	0.00193	CcSEcCtD
Acamprosate—Asthenia—Cisplatin—esophageal cancer	0.00129	0.00192	CcSEcCtD
Acamprosate—Skin disorder—Capecitabine—esophageal cancer	0.00128	0.00192	CcSEcCtD
Acamprosate—Hyperhidrosis—Capecitabine—esophageal cancer	0.00128	0.00191	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—PFN1—esophageal cancer	0.00127	0.00384	CbGpPWpGaD
Acamprosate—Anorexia—Capecitabine—esophageal cancer	0.00126	0.00188	CcSEcCtD
Acamprosate—GRIN2A—Neuronal System—GNG7—esophageal cancer	0.00125	0.00379	CbGpPWpGaD
Acamprosate—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00125	0.00379	CbGpPWpGaD
Acamprosate—Immune system disorder—Methotrexate—esophageal cancer	0.00125	0.00187	CcSEcCtD
Acamprosate—Chills—Methotrexate—esophageal cancer	0.00124	0.00186	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—PFN1—esophageal cancer	0.00124	0.00374	CbGpPWpGaD
Acamprosate—Hypotension—Capecitabine—esophageal cancer	0.00123	0.00184	CcSEcCtD
Acamprosate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00123	0.00372	CbGpPWpGaD
Acamprosate—Diarrhoea—Cisplatin—esophageal cancer	0.00123	0.00183	CcSEcCtD
Acamprosate—Alopecia—Methotrexate—esophageal cancer	0.00122	0.00183	CcSEcCtD
Acamprosate—Mental disorder—Methotrexate—esophageal cancer	0.00121	0.00181	CcSEcCtD
Acamprosate—Malnutrition—Methotrexate—esophageal cancer	0.00121	0.0018	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.0012	0.0018	CcSEcCtD
Acamprosate—Insomnia—Capecitabine—esophageal cancer	0.0012	0.00179	CcSEcCtD
Acamprosate—GRIN1—EPH-Ephrin signaling—KDR—esophageal cancer	0.00119	0.00361	CbGpPWpGaD
Acamprosate—Paraesthesia—Capecitabine—esophageal cancer	0.00119	0.00177	CcSEcCtD
Acamprosate—Dysgeusia—Methotrexate—esophageal cancer	0.00118	0.00176	CcSEcCtD
Acamprosate—Dyspnoea—Capecitabine—esophageal cancer	0.00118	0.00176	CcSEcCtD
Acamprosate—GRIN1—Alzheimers Disease—CASP8—esophageal cancer	0.00118	0.00356	CbGpPWpGaD
Acamprosate—GRIN2A—Neuronal System—ALDH2—esophageal cancer	0.00117	0.00355	CbGpPWpGaD
Acamprosate—Back pain—Methotrexate—esophageal cancer	0.00117	0.00174	CcSEcCtD
Acamprosate—GRIN2B—EPH-Ephrin signaling—KDR—esophageal cancer	0.00116	0.00352	CbGpPWpGaD
Acamprosate—Dyspepsia—Capecitabine—esophageal cancer	0.00116	0.00174	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—AKAP13—esophageal cancer	0.00116	0.0035	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00115	0.00348	CbGpPWpGaD
Acamprosate—Decreased appetite—Capecitabine—esophageal cancer	0.00115	0.00172	CcSEcCtD
Acamprosate—GRIN2B—Alzheimers Disease—CASP8—esophageal cancer	0.00115	0.00347	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00114	0.0017	CcSEcCtD
Acamprosate—Vomiting—Cisplatin—esophageal cancer	0.00114	0.0017	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00113	0.00342	CbGpPWpGaD
Acamprosate—Rash—Cisplatin—esophageal cancer	0.00113	0.00169	CcSEcCtD
Acamprosate—Constipation—Capecitabine—esophageal cancer	0.00113	0.00169	CcSEcCtD
Acamprosate—Pain—Capecitabine—esophageal cancer	0.00113	0.00169	CcSEcCtD
Acamprosate—Dermatitis—Cisplatin—esophageal cancer	0.00113	0.00169	CcSEcCtD
Acamprosate—Ill-defined disorder—Methotrexate—esophageal cancer	0.00112	0.00167	CcSEcCtD
Acamprosate—Anaemia—Methotrexate—esophageal cancer	0.00111	0.00166	CcSEcCtD
Acamprosate—GRIN2B—ErbB4 signaling events—PIK3CA—esophageal cancer	0.0011	0.00334	CbGpPWpGaD
Acamprosate—GRIN1—Neuronal System—GNG7—esophageal cancer	0.00109	0.0033	CbGpPWpGaD
Acamprosate—Feeling abnormal—Capecitabine—esophageal cancer	0.00109	0.00163	CcSEcCtD
Acamprosate—Malaise—Methotrexate—esophageal cancer	0.00109	0.00162	CcSEcCtD
Acamprosate—Vertigo—Methotrexate—esophageal cancer	0.00108	0.00162	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—KMT2D—esophageal cancer	0.00108	0.00327	CbGpPWpGaD
Acamprosate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00108	0.00161	CcSEcCtD
Acamprosate—Leukopenia—Methotrexate—esophageal cancer	0.00108	0.00161	CcSEcCtD
Acamprosate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00107	0.00325	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—GNG7—esophageal cancer	0.00107	0.00322	CbGpPWpGaD
Acamprosate—Nausea—Cisplatin—esophageal cancer	0.00106	0.00159	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—PDE4D—esophageal cancer	0.00106	0.0032	CbGpPWpGaD
Acamprosate—Cough—Methotrexate—esophageal cancer	0.00105	0.00157	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—AKAP13—esophageal cancer	0.00105	0.00318	CbGpPWpGaD
Acamprosate—Urticaria—Capecitabine—esophageal cancer	0.00105	0.00157	CcSEcCtD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00105	0.00316	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00104	0.00316	CbGpPWpGaD
Acamprosate—Body temperature increased—Capecitabine—esophageal cancer	0.00104	0.00156	CcSEcCtD
Acamprosate—Abdominal pain—Capecitabine—esophageal cancer	0.00104	0.00156	CcSEcCtD
Acamprosate—Convulsion—Methotrexate—esophageal cancer	0.00104	0.00156	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—CFL1—esophageal cancer	0.00103	0.00311	CbGpPWpGaD
Acamprosate—Arthralgia—Methotrexate—esophageal cancer	0.00103	0.00153	CcSEcCtD
Acamprosate—Myalgia—Methotrexate—esophageal cancer	0.00103	0.00153	CcSEcCtD
Acamprosate—Chest pain—Methotrexate—esophageal cancer	0.00103	0.00153	CcSEcCtD
Acamprosate—GRIN1—Neuronal System—ALDH2—esophageal cancer	0.00102	0.0031	CbGpPWpGaD
Acamprosate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00102	0.00152	CcSEcCtD
Acamprosate—Discomfort—Methotrexate—esophageal cancer	0.00101	0.00151	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00101	0.00305	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—GNG7—esophageal cancer	0.00101	0.00305	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—CFL1—esophageal cancer	0.001	0.00303	CbGpPWpGaD
Acamprosate—GRIN2B—Neuronal System—ALDH2—esophageal cancer	0.000998	0.00302	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TLR4—esophageal cancer	0.000995	0.00301	CbGpPWpGaD
Acamprosate—Confusional state—Methotrexate—esophageal cancer	0.000992	0.00148	CcSEcCtD
Acamprosate—Anaphylactic shock—Methotrexate—esophageal cancer	0.000984	0.00147	CcSEcCtD
Acamprosate—Infection—Methotrexate—esophageal cancer	0.000977	0.00146	CcSEcCtD
Acamprosate—Hypersensitivity—Capecitabine—esophageal cancer	0.000974	0.00145	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—ADCYAP1—esophageal cancer	0.000963	0.00291	CbGpPWpGaD
Acamprosate—Thrombocytopenia—Methotrexate—esophageal cancer	0.000963	0.00144	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—PDE4D—esophageal cancer	0.000961	0.00291	CbGpPWpGaD
Acamprosate—Skin disorder—Methotrexate—esophageal cancer	0.000956	0.00143	CcSEcCtD
Acamprosate—Hyperhidrosis—Methotrexate—esophageal cancer	0.000951	0.00142	CcSEcCtD
Acamprosate—Asthenia—Capecitabine—esophageal cancer	0.000948	0.00142	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—NOS2—esophageal cancer	0.000947	0.00286	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000941	0.00285	CbGpPWpGaD
Acamprosate—Anorexia—Methotrexate—esophageal cancer	0.000938	0.0014	CcSEcCtD
Acamprosate—Pruritus—Capecitabine—esophageal cancer	0.000935	0.0014	CcSEcCtD
Acamprosate—GABRG2—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000924	0.00279	CbGpPWpGaD
Acamprosate—Hypotension—Methotrexate—esophageal cancer	0.000919	0.00137	CcSEcCtD
Acamprosate—GRM5—Signaling by GPCR—GNG7—esophageal cancer	0.000914	0.00277	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—PFN1—esophageal cancer	0.000906	0.00274	CbGpPWpGaD
Acamprosate—Diarrhoea—Capecitabine—esophageal cancer	0.000904	0.00135	CcSEcCtD
Acamprosate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000896	0.00134	CcSEcCtD
Acamprosate—Insomnia—Methotrexate—esophageal cancer	0.00089	0.00133	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—CXCL2—esophageal cancer	0.000887	0.00268	CbGpPWpGaD
Acamprosate—Paraesthesia—Methotrexate—esophageal cancer	0.000883	0.00132	CcSEcCtD
Acamprosate—GRIN2B—Developmental Biology—PFN1—esophageal cancer	0.000883	0.00267	CbGpPWpGaD
Acamprosate—GABRB3—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000882	0.00267	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—WWOX—esophageal cancer	0.000881	0.00267	CbGpPWpGaD
Acamprosate—Dyspnoea—Methotrexate—esophageal cancer	0.000877	0.00131	CcSEcCtD
Acamprosate—Somnolence—Methotrexate—esophageal cancer	0.000875	0.00131	CcSEcCtD
Acamprosate—GRIN1—Axon guidance—ACTB—esophageal cancer	0.000874	0.00264	CbGpPWpGaD
Acamprosate—Dizziness—Capecitabine—esophageal cancer	0.000874	0.00131	CcSEcCtD
Acamprosate—Dyspepsia—Methotrexate—esophageal cancer	0.000866	0.00129	CcSEcCtD
Acamprosate—GABRG2—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000866	0.00262	CbGpPWpGaD
Acamprosate—GRIN2C—Alzheimers Disease—TP53—esophageal cancer	0.000858	0.00259	CbGpPWpGaD
Acamprosate—Decreased appetite—Methotrexate—esophageal cancer	0.000855	0.00128	CcSEcCtD
Acamprosate—GRIN2B—Axon guidance—ACTB—esophageal cancer	0.000852	0.00258	CbGpPWpGaD
Acamprosate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000849	0.00127	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—RB1—esophageal cancer	0.000847	0.00256	CbGpPWpGaD
Acamprosate—Pain—Methotrexate—esophageal cancer	0.000841	0.00126	CcSEcCtD
Acamprosate—Vomiting—Capecitabine—esophageal cancer	0.00084	0.00126	CcSEcCtD
Acamprosate—GRM5—Signaling Pathways—FKBP1A—esophageal cancer	0.000838	0.00254	CbGpPWpGaD
Acamprosate—Rash—Capecitabine—esophageal cancer	0.000833	0.00124	CcSEcCtD
Acamprosate—Dermatitis—Capecitabine—esophageal cancer	0.000832	0.00124	CcSEcCtD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000832	0.00252	CbGpPWpGaD
Acamprosate—Headache—Capecitabine—esophageal cancer	0.000828	0.00124	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—ANXA1—esophageal cancer	0.000825	0.00249	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—WIF1—esophageal cancer	0.000819	0.00248	CbGpPWpGaD
Acamprosate—Feeling abnormal—Methotrexate—esophageal cancer	0.000811	0.00121	CcSEcCtD
Acamprosate—GABRA1—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000807	0.00244	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—CXCL2—esophageal cancer	0.000806	0.00244	CbGpPWpGaD
Acamprosate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000804	0.0012	CcSEcCtD
Acamprosate—GRM5—GPCR downstream signaling—SST—esophageal cancer	0.000802	0.00243	CbGpPWpGaD
Acamprosate—GRIN2D—Alzheimers Disease—TP53—esophageal cancer	0.000797	0.00241	CbGpPWpGaD
Acamprosate—Nausea—Capecitabine—esophageal cancer	0.000785	0.00117	CcSEcCtD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—SST—esophageal cancer	0.000785	0.00237	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—GHRL—esophageal cancer	0.000782	0.00236	CbGpPWpGaD
Acamprosate—Urticaria—Methotrexate—esophageal cancer	0.000782	0.00117	CcSEcCtD
Acamprosate—Body temperature increased—Methotrexate—esophageal cancer	0.000778	0.00116	CcSEcCtD
Acamprosate—Abdominal pain—Methotrexate—esophageal cancer	0.000778	0.00116	CcSEcCtD
Acamprosate—GABRA1—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000757	0.00229	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CSNK1A1—esophageal cancer	0.000756	0.00229	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—ANXA1—esophageal cancer	0.000749	0.00227	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CFL1—esophageal cancer	0.000734	0.00222	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—SST—esophageal cancer	0.000728	0.0022	CbGpPWpGaD
Acamprosate—Hypersensitivity—Methotrexate—esophageal cancer	0.000725	0.00108	CcSEcCtD
Acamprosate—GABRB3—Neuronal System—GNG7—esophageal cancer	0.000721	0.00218	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000717	0.00217	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CFL1—esophageal cancer	0.000715	0.00216	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—GHRL—esophageal cancer	0.00071	0.00215	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—SOX2—esophageal cancer	0.000709	0.00214	CbGpPWpGaD
Acamprosate—GABRG2—Neuronal System—GNG7—esophageal cancer	0.000708	0.00214	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PFN1—esophageal cancer	0.000707	0.00214	CbGpPWpGaD
Acamprosate—Asthenia—Methotrexate—esophageal cancer	0.000706	0.00105	CcSEcCtD
Acamprosate—GRIN1—Spinal Cord Injury—PTGS2—esophageal cancer	0.000696	0.00211	CbGpPWpGaD
Acamprosate—Pruritus—Methotrexate—esophageal cancer	0.000696	0.00104	CcSEcCtD
Acamprosate—GRM5—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000696	0.0021	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000691	0.00209	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—SOX2—esophageal cancer	0.000691	0.00209	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.00068	0.00206	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000679	0.00205	CbGpPWpGaD
Acamprosate—GABRB3—Neuronal System—ALDH2—esophageal cancer	0.000675	0.00204	CbGpPWpGaD
Acamprosate—Diarrhoea—Methotrexate—esophageal cancer	0.000673	0.00101	CcSEcCtD
Acamprosate—GABRG2—Neuronal System—ALDH2—esophageal cancer	0.000663	0.00201	CbGpPWpGaD
Acamprosate—GRIN2A—Alzheimers Disease—TP53—esophageal cancer	0.000655	0.00198	CbGpPWpGaD
Acamprosate—Dizziness—Methotrexate—esophageal cancer	0.000651	0.000972	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00065	0.00197	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000638	0.00193	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000637	0.00193	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ELMO1—esophageal cancer	0.000635	0.00192	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—CCND1—esophageal cancer	0.000629	0.0019	CbGpPWpGaD
Acamprosate—Vomiting—Methotrexate—esophageal cancer	0.000626	0.000934	CcSEcCtD
Acamprosate—GRIN1—Developmental Biology—ACTB—esophageal cancer	0.000624	0.00189	CbGpPWpGaD
Acamprosate—GRM5—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000622	0.00188	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—AKAP13—esophageal cancer	0.000621	0.00188	CbGpPWpGaD
Acamprosate—GABRB3—Orphan transporters—CREBBP—esophageal cancer	0.00062	0.00188	CbGpPWpGaD
Acamprosate—Rash—Methotrexate—esophageal cancer	0.00062	0.000927	CcSEcCtD
Acamprosate—Dermatitis—Methotrexate—esophageal cancer	0.00062	0.000926	CcSEcCtD
Acamprosate—GABRA1—Neuronal System—GNG7—esophageal cancer	0.000619	0.00187	CbGpPWpGaD
Acamprosate—Headache—Methotrexate—esophageal cancer	0.000616	0.000921	CcSEcCtD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000616	0.00186	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CTNNA1—esophageal cancer	0.000613	0.00185	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000611	0.00185	CbGpPWpGaD
Acamprosate—GABRG2—Orphan transporters—CREBBP—esophageal cancer	0.000609	0.00184	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—ACTB—esophageal cancer	0.000608	0.00184	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000605	0.00183	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CTNNA1—esophageal cancer	0.000598	0.00181	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000593	0.00179	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000588	0.00178	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—ABL1—esophageal cancer	0.000585	0.00177	CbGpPWpGaD
Acamprosate—Nausea—Methotrexate—esophageal cancer	0.000584	0.000873	CcSEcCtD
Acamprosate—GABRA1—Neuronal System—ALDH2—esophageal cancer	0.00058	0.00175	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000577	0.00175	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000573	0.00173	CbGpPWpGaD
Acamprosate—GRIN1—Alzheimers Disease—TP53—esophageal cancer	0.000571	0.00173	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—ABL1—esophageal cancer	0.000571	0.00173	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PDE4D—esophageal cancer	0.000568	0.00172	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000564	0.0017	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000564	0.0017	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000558	0.00169	CbGpPWpGaD
Acamprosate—GRIN2B—Alzheimers Disease—TP53—esophageal cancer	0.000557	0.00168	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000553	0.00167	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000553	0.00167	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—GNG7—esophageal cancer	0.00054	0.00163	CbGpPWpGaD
Acamprosate—GABRA1—Orphan transporters—CREBBP—esophageal cancer	0.000533	0.00161	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000529	0.0016	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—XIAP—esophageal cancer	0.000506	0.00153	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000505	0.00153	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—MYC—esophageal cancer	0.000505	0.00153	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—EGFR—esophageal cancer	0.000493	0.00149	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000484	0.00146	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000484	0.00146	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CTNNA1—esophageal cancer	0.000479	0.00145	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CXCL2—esophageal cancer	0.000476	0.00144	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000471	0.00143	CbGpPWpGaD
Acamprosate—GRIN1—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000463	0.0014	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PSME2—esophageal cancer	0.000445	0.00134	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PSME1—esophageal cancer	0.000445	0.00134	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—KDR—esophageal cancer	0.000444	0.00134	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ANXA1—esophageal cancer	0.000442	0.00134	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—MET—esophageal cancer	0.000434	0.00131	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—KDR—esophageal cancer	0.000432	0.00131	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SST—esophageal cancer	0.00043	0.0013	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000427	0.00129	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—MET—esophageal cancer	0.000423	0.00128	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000419	0.00127	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NOTCH3—esophageal cancer	0.000419	0.00127	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—GHRL—esophageal cancer	0.000419	0.00127	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—ABL1—esophageal cancer	0.000418	0.00126	CbGpPWpGaD
Acamprosate—GRIN1—Spinal Cord Injury—TP53—esophageal cancer	0.000414	0.00125	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—FBXW7—esophageal cancer	0.000413	0.00125	CbGpPWpGaD
Acamprosate—SLC36A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000409	0.00124	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—ABL1—esophageal cancer	0.000407	0.00123	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—SMAD4—esophageal cancer	0.000405	0.00122	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—SMAD4—esophageal cancer	0.000394	0.00119	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000388	0.00117	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000385	0.00116	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000381	0.00115	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NOTCH2—esophageal cancer	0.000376	0.00114	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000367	0.00111	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TGFBR2—esophageal cancer	0.000334	0.00101	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000333	0.00101	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—ERBB2—esophageal cancer	0.000317	0.00096	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—KDR—esophageal cancer	0.000317	0.000958	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—SMAD4—esophageal cancer	0.000316	0.000955	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—MET—esophageal cancer	0.00031	0.000937	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—ERBB2—esophageal cancer	0.000309	0.000936	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—KDR—esophageal cancer	0.000309	0.000933	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—MET—esophageal cancer	0.000302	0.000913	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—NOTCH1—esophageal cancer	0.000298	0.000902	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—NOTCH1—esophageal cancer	0.000291	0.000879	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—CREBBP—esophageal cancer	0.00027	0.000818	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—CREBBP—esophageal cancer	0.000264	0.000797	CbGpPWpGaD
Acamprosate—GABRA1—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000262	0.000793	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—HIF1A—esophageal cancer	0.000258	0.000782	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—KDR—esophageal cancer	0.000247	0.000748	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000236	0.000714	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NOTCH1—esophageal cancer	0.000233	0.000704	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000232	0.000701	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000227	0.000686	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—ERBB2—esophageal cancer	0.000226	0.000685	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000223	0.000673	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—ERBB2—esophageal cancer	0.000221	0.000668	CbGpPWpGaD
Acamprosate—GRIN1—Axon guidance—EGFR—esophageal cancer	0.00022	0.000665	CbGpPWpGaD
Acamprosate—GRIN2B—Axon guidance—EGFR—esophageal cancer	0.000214	0.000649	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CREBBP—esophageal cancer	0.000211	0.000639	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—EGFR—esophageal cancer	0.000207	0.000627	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000203	0.000613	CbGpPWpGaD
Acamprosate—GRM5—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000198	0.0006	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000195	0.000588	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—NOS3—esophageal cancer	0.000189	0.000572	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EP300—esophageal cancer	0.000184	0.000557	CbGpPWpGaD
Acamprosate—GRM5—Signaling by GPCR—PIK3CA—esophageal cancer	0.00018	0.000545	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EP300—esophageal cancer	0.00018	0.000543	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—ERBB2—esophageal cancer	0.000177	0.000535	CbGpPWpGaD
Acamprosate—GRIN1—Developmental Biology—EGFR—esophageal cancer	0.000157	0.000475	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CCND1—esophageal cancer	0.000156	0.000472	CbGpPWpGaD
Acamprosate—GRIN2B—Developmental Biology—EGFR—esophageal cancer	0.000153	0.000463	CbGpPWpGaD
Acamprosate—GABRB3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000151	0.000458	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—CDKN1A—esophageal cancer	0.000151	0.000457	CbGpPWpGaD
Acamprosate—GABRG2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000149	0.00045	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EP300—esophageal cancer	0.000144	0.000435	CbGpPWpGaD
Acamprosate—GABRA1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.00013	0.000393	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—MYC—esophageal cancer	0.000125	0.000379	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—EGFR—esophageal cancer	0.000123	0.000371	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—PIK3CA—esophageal cancer	0.000106	0.000322	CbGpPWpGaD
Acamprosate—GRM5—Signaling Pathways—TP53—esophageal cancer	0.000103	0.000311	CbGpPWpGaD
